US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) ニュース

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/24	06 : 05	PR Newswire (US)	Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/22	06 : 05	PR Newswire (US)	Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/18	06 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/16	06 : 19	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/08	22 : 30	PR Newswire (US)	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/07	06 : 01	PR Newswire (US)	Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/04	06 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2025/01/01	06 : 17	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	22 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	22 : 00	PR Newswire (US)	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	06 : 47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/20	06 : 37	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/18	06 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/14	08 : 55	PR Newswire (US)	Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/12/04	08 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/30	03 : 41	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/27	06 : 01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in December	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/13	07 : 58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/08	09 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/07	22 : 30	PR Newswire (US)	Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/06	06 : 01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in November	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/04	22 : 30	PR Newswire (US)	Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/04	22 : 25	PR Newswire (US)	Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/02	08 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/11/01	21 : 31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20 : 04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/30	20 : 00	PR Newswire (US)	Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/12	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/10/10	05 : 01	PR Newswire (US)	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results	NASDAQ:NBIX	Neurocrine Biosciences Inc

Showing the most relevant articles for your search:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 次へ >>

Invesco QQQ Trust Series 1

American Express

Financial Select Sector

US Dollar vs Euro

Gold vs US Dollar

BNP Paribas (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約